Advarra Appears to Out Maneuver WCG in the Gene Therapy Clinical Trials Space

Advarra Appears to Out Maneuver WCG in the Gene Therapy Clinical Trials Space

Has Advarra established the market’s leading network of registered trial sites focusing on gene therapy studies? Put more specifically, has the commercial institutional review board (IRB)-based company now emerged as a leading force in supporting gene-based therapy development because of its position as offering a top institutional biosafety committee (IBC) network? The pharmaceutical clinical development vendor specializing in regulatory review solutions, research quality, compliance consulting, and clinical trial site-centric technology products makes the case that it has via the Advarra Gene Therapy™ Ready site network, with what amounts to over 500 registered trial sites identified by the NIH as associated with gene therapy studies. With the need to ramp up pre-qualified sites with gene therapy-based competency and expertise, adhering to sound and rational quality principles relevant to the gene therapy domain, Advarra suggests they can save CROs and sponsors a month of time, which for some blockbuster prospects, represents about an $80 million time savings.

As commercial IRBs now have big private equity backers, they are on an acquisitive tear, seeking growth and market po...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee